Viome has acquired Circulate for an undisclosed amount, adding a clinical therapeutic platform to its existing diagnostics and microbiome testing business. The deal brings Circulate’s Therapeutic Plasma Exchange (TPE) technology under Viome’s control, expanding the company’s reach from analysis into active intervention.
Circulate develops and operates TPE, an evidence-based treatment designed to remove toxic, inflammatory, disease-causing, and age-accelerating substances from the bloodstream. Its patented flagship product is already in use, with the company positioning itself as a pioneer in technologies aimed at reversing aging and improving health outcomes. Viome, known for its work in microbiome testing and precision health, has built its reputation on rigorous scientific research and clinical trials. The acquisition allows Viome to integrate Circulate’s therapeutic capabilities with its own diagnostic data, creating a more complete health management loop.
The strategic rationale centers on vertical integration. Viome can now identify biological imbalances through its testing and address them directly with Circulate’s TPE treatments, rather than referring patients elsewhere. This combination is expected to shorten the path from biomarker discovery to clinical application, particularly in the aging and chronic disease space. For Circulate, joining Viome provides access to a broader patient base and a research infrastructure that can accelerate further clinical validation of its platform.
The combined entity will operate across diagnostics and therapeutics, with TPE serving as a flagship offering alongside Viome’s existing product lines. Both companies have emphasized a science-first approach, which may ease integration of their respective research teams. The immediate focus will be on scaling Circulate’s treatment availability while continuing ongoing trials. Over the next several quarters, the merged operation aims to demonstrate how pairing molecular insights with a direct therapeutic intervention can produce measurable health outcomes in real-world settings.